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Background: Endometrial cancers (ECs) are the most common form of gynecologic malignancy. Recent studies
have reported that ECs reveal distinct markers for molecular pathogenesis, which in turn is linked to the various
histological types of ECs. To understand further the molecular events contributing to ECs and endometrial
tumorigenesis in general, a more precise identification of cancer-associated molecules and signaling networks
would be useful for the detection and monitoring of malignancy, improving clinical cancer therapy, and
personalization of treatments.
Results: ECs-specific gene co-expression networks were constructed by differential expression analysis and weighted
gene co-expression network analysis (WGCNA). Important pathways and putative cancer hub genes contribution to
tumorigenesis of ECs were identified. An elastic-net regularized classification model was built using the cancer hub
gene signatures to predict the phenotypic characteristics of ECs. The 19 cancer hub gene signatures had high
predictive power to distinguish among three key principal features of ECs: grade, type, and stage. Intriguingly,
these hub gene networks seem to contribute to ECs progression and malignancy via cell-cycle regulation, antigen
processing and the citric acid (TCA) cycle.
Conclusions: The results of this study provide a powerful biomarker discovery platform to better understand the
progression of ECs and to uncover potential therapeutic targets in the treatment of ECs. This information might
lead to improved monitoring of ECs and resulting improvement of treatment of ECs, the 4th most common of
cancer in women.
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Endometrial cancers (ECs) are the most common type of
uterine cancer. With more than 280,000 cases occurring
annually worldwide, it has become the fourth most com-
mon cancer in women worldwide [1]. The incidence rate
of ECs is higher than uterine cervix cancer and ovarian
cancer in the United State [2]. These tumors have been
broadly classified into two major subtypes I and II, based
on the clinic-pathological characteristics such as progno-
sis and aggressiveness, as well as, molecular alterations
that impact tumor response to therapies [3]. Type I tu-
mors are the most frequent subtype which have been
linked to obesity, estrogen excess, and low-grade (diffe-
rentiated) inflammation. Type II endometrial tumors are* Correspondence: cychuang@mx.nthu.edu.tw
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unless otherwise stated.serous carcinoma that have been associated with older,
non-obese, post-menopausal women, high-grade (un-
differentiated), and also with worst outcomes. It has
been suggested that the molecular-genetic alterations
may be responsible for the distinct morphology and bio-
logic behavior of the different subtypes of human ECs
[4]. For example, low-grade or early-stage Type I tumors
may progress to high-grade or late-stage; nonetheless Type
I and II cancers appear to be separate entities in most
cases, and different molecular abnormalities would result
in unique cellular functions and distinctive tumor mor-
phology [5]. Therefore, it is crucial to discover with more
accuracy the putative molecular signatures of ECs, which
should allow for improved detection and monitoring of
endometrial tumorigenesis, since such knowledge could
be beneficial for early diagnostic, enhanced prognostic,
and more effective therapeutic strategies.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Chou et al. BMC Genomics 2014, 15:300 Page 2 of 12
http://www.biomedcentral.com/1471-2164/15/300ECs are characterized by a variety of genetic alterations
and significant gene expression modifications. Over the
last decade, multiple studies have identified aberrant gene
expression of several important genes in ECs, with the
mutation frequency varying according to the histological
classification [6]. Type I tumors are frequently charac-
terized by the loss or altered expression of phosphatase
and tensin homolog (PTEN). PTEN modulates cell sur-
vival and proliferation through its effects on downstream
factors, mainly phospholipid phosphatidylinositol (3, 4, 5)-
triphosphate (PIP3) and protein kinase B (PKB, Akt).
PTEN inactivation leads to a decrease of lipid and protein
phosphatase activity and promotes cell cycle progres-
sion to the G1/S phase [7]. Other genes are linked
to abnormalities in Type I tumors includingβ-catenin,
K-ras and DNA-mismatch repair genes [7-10]. In com-
parison, Type II tumors have been reported to be asso-
ciated with abnormalities in TP53 and Her2/neu [6].
The gene TP53 encodes a tumor suppressor p53, the most
frequently mutated protein in cancer. P53 prevents cell
cycle progression after DNA damage, inducing cell arrest
and apoptosis through several regulator proteins such as
p21, Cyclin D1, and RB1. TP53 mutations occur as an
early event in Type II tumorigenesis and may occur as
manifestations of late-stage molecular changes in Type I
lesions. Overexpression of Her-2/neu observed in Type II
carcinomas has been linked to coding alterations for a
transmembrane receptor tyrosine kinase involved in cell
signaling [11]. Although these studies provide important
insights into the molecular basis of endometrial cancers,
a limited set of well-known cancer genes was obtained
from these studies. In fact, until now, a large-scale
screen of the gene expression analyses incorporating
systematic methods to discover cancer subtypes and
their molecular alterations in ECs has not been globally
conducted and explored.
Recent advances in constructing genetic network ap-
proaches have enabled the unprecedented characterization
of studying a variety of somatic alterations and gene
expression in cancer genomes. Therefore, these advances
allow connecting the existent gap of understanding the
association of individual genes to complex diseases such
as cancer by the systematic investigation of the observed
relationship between gene products and tumorigenesis. A
weighted gene co-expression network approach (WGCNA)
has been proposed to reconstruct gene co-expression net-
works (modules) in terms of large-scale gene expression
profiles and as well as for the distinction of centrally located
genes (hub genes) driving key cellular signaling pathways
[12,13]. The WGCNA approach provides a functional inter-
pretation in Systems Biology and leads to new insights
into cancer pathophysiology [14-17].
Here, we aimed to establish a systematic framework
for constructing for the first time, the ECs-associatedgene co-expression networks and pin-pointing cancer
hub genes contributing to endometrial tumorigenesis
and progression. This study provides a novel and broad
application platform for the identification of cancer
gene signatures of ECs tumorigensis and for the discovery
of potential new molecular targets for the development of
more effective therapies for the treatment of ECs.
Results
Systematic framework for identifying cancer hub genes in
ECs
In this study, a novel systematic analysis was developed
to integrate WGCNA and elastic-net analysis to identify
cancer hub genes in ECs (Figure 1). This method is di-
vided into three main parts. First, we performed a very
large human microarray-based ECs meta-analysis by
merging multiple platforms to reveal the differentially
expressed genes on 273 EC samples properly matched
with normal samples. Second, we conducted the WGCNA
analysis to reconstruct EC-associated gene co-expression
networks (modules) and discover the cancer hub genes.
Third, we developed a cancer hub genes-based classifier
model to distinguish the phenotypic characteristics of ECs
(i.e., grade, type and stage). Finally, we used the hub genes
as the gene signatures to validate its biological and
phenotypic characteristics relevance using 10-fold cross-
validation and independent data set validation. Figure 1
presents an overview of approach in this study, and the
detailed methods are described in Supporting Information
(Additional file 1: SI Materials and Methods).
Reconstruction of EC-specific gene co-expression network
In the initial analysis, we identified 3,920 genes having
significant expression difference between subjects with
cancer and subjects without cancer by applying a 1% FDR
(Additional file 2: Table S1). These endometrial cancer-
related genes were used to reconstruct the EC-associated
co-expression network (module) and identify a number
of modules of high co-expression genes. As shown in
Figure 2, these modules are significantly enriched for
biologically important processes that are relevant to can-
cer, including cell-cycle regulation, antigen processing,
immune response, and cell adhesion (Table 1). Among the
modules, yellow-colored module (Myellow) that specifically
corresponds to clinical information of ECs, showed a
high Pearson correlation with phenotypic characteristics
of ECs including grade (r = 0.44, Bonferroni-adjusted
p-value = 1.2E−16), type (r = 0.34, Bonferroni-adjusted
p-value = 6.3E−9) and stage (r = 0.31, Bonferroni-adjusted
p-value = 2.1E−7) in ECs. The blue-colored module (Mblue)
was only significantly correlated with the stage of ECs
(r = 0.42, Bonferroni-adjusted p-value = 6.0E−19). By con-
trast, other modules showed a much lower correlation
with the phenotypic characteristics of ECs. Interestingly,
Figure 1 Framework for deriving the cancer hub genes and validating its phenotypic relevance in ECs: (A) Data collection and
processing for 273 microarray experiments to find 3,920 DEGs, (B) Identification of ECs-specific module and 19 cancer hub genes,
and (C) Developed a cancer hub genes-based classifier model using 10-fold cross validation and ROC curves to assess the prediction
accuracy of model.
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cycle regulation (Bonferroni-adjusted p-value = 1.2E−31).
Conversely, Mblue gene ontology categories included anti-
gen processing (Bonferroni-adjusted p-value = 8.7E−12)
and the citric acid (tricarboxylic acid; TCA) cycle (Bonfer-
roni-adjusted p-value = 4.5E−12).
Identification of cancer hub genes
Genes with the highest degree of connectivity within a
module (centrally located genes of co-expressed genes) are
termed hub genes and are expected to be drivers required
for signaling pathways of essential cellular function. Toidentify the cancer hub genes in the Myellow and Mblue
modules, we estimated the scale connectivity (K) for
each gene and for gene significance (GS) based on its
Pearson correlation with phenotypic characteristics of
ECs (Additional file 3: Table S2) and predicted the fre-
quency (f ) by using the elastic net regression model
combined with bootstrap approaches in the modules
(Figure 3). We set the weighted cutoff value (defined as
r > 0.2, K > 0.25 and f > 750) to identify cancer hub genes
with strongest connections to other genes and to link to
phenotypic characteristics of ECs. As a result, we identi-
fied 19 cancer hub genes with at least 50 connections
Figure 2 WGCNA analysis on the large-scale microarray datasets. (A) Dendrogram showing relationship for the topological overlap of genes
and their relationship to modules, which are color-coded. (B) Graphic depiction of the blue-color module (Mblue), green-color module (Mgreen),
turquoise-color module (Mturquoise) and yellow-color module (Myellow) using Cytoscape. For each viewing module, pairs of genes with the highest
intramodular topological overlap are illustrated, with each link corresponding to a topology overlap measure (TOM) between the connected nodes.
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Table 1 Module significance in ECs and GO analysis
Module Correlationa with phenotypic characteristics of ECs (p-value) Gene ontology enrichment analysis
Grade Type Stage Term p-valueb FDR
Blue −0.002 (9.0E−1) 0.08 (2.2E−1) 0.42 (6.0E−19) Antigen processing 8.7E−12 1.7E−12
TCA cycle 4.5E−12 2.1E−12
Green 0.006 (9.1E−1) −0.02 (6.1E−5) 0.01 (9.3E−1) Immune response 3.7E−43 6.3E−40
Turquoise −0.17 (6.4E−3) −0.19 (2.4E−3) 0.17 (6.2E−3) Cell adhesion 2.9E−29 1.1E−29
Yellow 0.44 (1.2E−16) 0.34 (6.3E−9) 0.31 (2.1E−7) Cell-cycle regulation 4.9E−35 8.6E−32
aThe correlation coefficient was calculated from the module eigengenes (i.e., first principal component of the expression values across subjects) and phenotypic
characteristics of ECs using Pearson correlation.
bp-value used the Bonferroni-adjusted p-value.
Figure 3 A systematic screen in ECs-associated networks identifies cancer hub genes. A plot representation of the elastic-net regression
gene selection results showing the Gene significance (GS, x-axis) and scaled gene connectivity (K, y-axis) of all genes of Myellow network that are
associated with (A) Grade, (B) Type, (C) Stage and that of the Mblue network that are associated with Stage (D). Each circle represents a single
phenotype-gene interaction and the size is proportional to the frequency (f) calculated from the elastic-net regression analysis. The red dashed
line indicates the cancer hub genes selection criteria (GS > 0.25, K > 0.2). Insets (1) - (4) are magnified views of selected cancer hub genes.
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genes associated with grade (TP53, BUB1, AURKB and
CENPA), type (AURKB, PRC1, CDC6, E2F2, KIF20A)
and stage (BUB1, FEN1, KIF23, CDC20 and PRC1) in
the Myellow, module. Nonetheless, 5 hub genes associ-
ated with stage including IDH3G, NDUFV2, ATP5B,
PSMB3 and PSMB7 were identified in the Mblue module
(Figure 3A-3D, Table 2). Figure 4 illustrated the rela-
tionship among these genes suggesting a complex regu-
latory gene network with varying topology.
Pathway analysis of hub genes
This study reconstructed and identified the gene net-
works of cancer hub genes to search the potential key
regulators of endometrial tumorigenesis and to identify
regulatory relationships among cancer hub genes. Using
functional enrichment analysis, we identified three major
signaling pathways; cell-cycle regulated networks (mitotic,
G2/M or G1/S phases), antigen processing (Class I MHC
antigen processing) and the TCA cycle, as the main
Gene Ontology biological processes overrepresented inTable 2 List of hub gene associated with grade, type and stag
Symbol Gene names
Hub genes for grade
TP53 Tumor protein 53
AURKB Aurora kinase B
BUB1 Budding uninhibited by benzimidazoles 1
CENPA Centromere protein A
Hub genes for type
AURKB Aurora kinase B
PRC1 Protein regulator of cytokinesis 1
CDC6 Cell division cycle 6
E2F2 E2F transcription factor 2
KIF20A Kinesin family member 20A
Hub genes for stage (derived from module yellow)
BUB1 Budding uninhibited by benzimidazoles 1
FEN1 Flap structure-specific endonuclease 1
KIF23 Kinesin family member 23
CDC20 Cell division cycle 20
PRC1 Protein regulator of cytokinesis 1
Hub genes for stage (derived from module blue)
IDH3G Isocitrate dehydrogenase 3 (NAD+) gamma
NDUFV2 NADH dehydrogenase (ubiquinone) flavoprotein 2
ATP5B ATP synthase, H + transporting, mitochondrial F1 compl
PSMB3 Proteasome (prosome, macropain) subunit, beta type, 3
PSMB7 Proteasome (prosome, macropain) subunit, beta type, 7
*This study defined the hub gene significance (HGS) by integrating WGCNA and ela
and frequency (f). Only genes present in GS > 0.2, K > 0.2 and f > 750 were selectedthe gene networks deriving from the cancer hub genes
(Figure 4). In the cell-cycle network, BUB1, AURKB,
CENPA, KIF20A, CDC20, CDC6, E2F2 and FEN1 seem
to regulate distinct co-expression pathways that con-
tributed to mitotic G2-G2/M phase, G2/M checkpoints,
and kinesins in Type II ECs, whereas these genes regu-
late the M phase and mitotic G1-G1/S phase in Type I
ECs (Figure 4A). In addition, the antigen processing and
TCA cycle networks are regulated by the hub genes
IDH3G, NDUFV2, ATP5B, PSMB3 and PSMB7, contri-
buting to tumorigenesis in Type II ECs (Figure 4B).
Cancer hub genes classification based model
This study performed receiver-operator characteristic
curve (ROC) analysis to assess the predictive accuracy of
the cancer hub gene signatures. As follows, an AUC (area
under curve) value of 0.5 indicated that the predictive
performance equals chance, while values greater than 0.5
indicated high predictive capacity. Using a strict 10-fold
cross-validation, the classification capacity of cancer hub
gene signatures proved to be significantly better thane o ECs
Hub gene significance*
f K GS
954 0.40 0.31
885 0.41 0.37
768 0.43 0.42
764 0.44 0.42
995 0.41 0.35
893 0.34 0.33
849 0.26 0.24
776 0.31 0.22
760 0.46 0.21
768 0.43 0.42
764 0.27 0.32
763 0.34 0.27
762 0.37 0.32
760 0.34 0.27
934 0.36 0.49
873 0.35 0.42
ex, beta polypeptide 769 0.52 0.49
762 0.41 0.47
760 0.32 0.42
stic-net analysis, estimating the gene significance (GS), scaled connectivity (K)
as ECs-specific hub genes.
Figure 4 Differentially activated pathways features between Type I and Type II ECs subtypes in (A) the cell‐cycle regulator network
and (B) the antigen processing network. Color arrows reflect pathway differences between subtypes (blue: Type I, red: Type II). Green lines
represent activation. A zoomed in view of the cancer hub gene signatures are also shown.
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S1D for second supporting information figure, p <10−6,
AUC = 0.72 ~ 0.85). Furthermore, the module showed a
substantial capacity to distinguish ECs grade (AUC = 0.91,
p < 10−12), type (AUC = 0.98, p < 10−5) and stage (Myellow:
AUC = 0.93, p < 10−12; Mblue: AUC = 0.73, p < 10
−4) in in-
dependent datasets (Figure 5). Strikingly, these hub genes
deriving from the co-expression networks of Myellow and
Mblue provided significant predictive power in distinguish-
ing the phenotypic characteristics of ECs.Discussion
In this study, we integrated a large-scale transcriptional
profiling of 273 ECs datasets to identify appropriate cancer
subtypes and biomarkers. Our long-term goal is to provide
insights into disease biology and diagnostic classification,
which may guide early-phase of clinical therapeutic applica-
tions. We also determined that co-expression networks
reflect causative relationships between different gene-gene
interactions. First, this study found that an EC-specific co-
expression network majorly regulated the tumorigenesis of
Type, AUC=0.98, P-value < 10-5
Grade, AUC=0.91, P-value < 10-12
Stage (derived from Myellow), AUC=0.93, P-value < 10-12
Stage (derived from Mblue), AUC=0.73, P-value < 10-6
Figure 5 ROC curve to assess the accuracy of the cancer hub
genes signature in the independent dataset. True positive rate
represent the model sensitivity, whereas false positive rate is one
minus the specificity or true negative rate and represents chance.
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play critical roles in cell cycle regulation but also
showed significant correlation with grade, type, and
stage of ECs. Second, 19 highly connected hub genes
were defined into two EC-associated co-expression net-
works. Detailed and systematic network analysis re-
vealed that these hub genes played roles as major
regulators in cell-cycle regulation, kinase modulation,
and the development of various tumors. Finally, for
independent analysis of microarray data as validated
data sets, these hub genes can provide excellent diag-
nostic power in distinguishing grade, type, and stage of
ECs. Altogether these findings strongly suggest that the
role of these hub genes in the EC-associated networks
may provide new insights into the underlying biological
mechanisms driving the tumorigenesis of ECs.
Tumor cell progression is typically associated with ab-
errant cell-cycle regulation, and this study identified
several unique hub genes in the networks associated
with the grade of ECs including TP53, BUB1, AURKB,
CENPA. In agreement with previous reports [17-20], the
disruption of these hub genes was observed in a variety of
human tumors and often correlates with tumorigenesis.
For example, BUB1 has been suggested to play a direct
role in the suppression of p53-mediated cell death via
physical interaction with p53 at kinetochores in re-
sponse to mitotic spindle damage [18]. Altered expres-
sion of BUB1 is associated with therapy failure and
death in patients with multiple types of cancer [19].
Fu et al. (2007) [20] reported a possible mechanism on
the roles of aurora kinases in mitosis and tumorigenesis.
They found that overexpression of AURKA and AURKB
disruption overrides spindle checkpoint, resulting in the
aneuploidy or polyploidy that occurs during cell div-
ision. When cells lose the normal function of p53, they
enter mitosis and become aneuploid, which is consid-
ered a cancerous manifestation.Recently, up-regulation of BUB1 gene has been linked
to the inhibition of p53-dependent senescence, hyper-
activation of AURKB and phosphorylation of CENP-A,
and might be considered as a potential oncogene in driv-
ing the aneuploidiation and tumorigenesis [21]. Interest-
ingly, this study found BUB1 not only highly connected
with other genes in the co-expression network, but also
significantly correlated with the transformation of ECs.
Therefore, BUB1 gene seems to modulate the expression
of tens or hundreds of genes suggesting that it might
allow undifferentiated cancer cells to overcome apop-
totic checkpoints favoring aberrant progression through
mitosis.
Previous reports suggested that PTEN mutations occur
early in the neoplastic process of Type I ECs and co-
exist frequently with other mutations in the PI(3)K/AKT
pathway [22], yet Type II ECs showed an alteration of
the E2F–retinoblastoma protein–p16 pathway by muta-
tions of p53 and p16 [23]. In this study, several unique
hub genes (AURKB, PRC1, CDC6, E2F2, KIF20A) were
identified in the co-expression network associated with
the subtype of ECs, which were linked to the PTEN and
p16-associated pathway. The cell division gene, CDC6, is
required for the cell cycle G1-to-S transition. Wu et al.
(2009) [24] have identified that CDC6 is the putative
PTEN target and demonstrated a causal linkage between
CDC6 and PTEN in metastatic human prostate cancer.
They indicated that the regulation of CDC6 expression
by PTEN is mediated through the E2F transcriptional
factor and the E2F2 protein. Furthermore, overexpres-
sion of AURKB has been suggested to compromise the
tumor suppressor function of p53 [25]. The gene PRC1,
encodes one of the polycomb-group proteins, and is
involved in cytokinesis. Of note, the PRC1 and PRC2/3/4
proteins can induce the repression of the PTEN tran-
scription via binding to the PTEN promoter region in
leukemic cells [26], while KIF20A is known to be con-
trolled by the E2F–retinoblastoma protein–p16 pathway,
and is linked to tumor aggressiveness in human hepatocel-
lular carcinomas [27]. Taken together, it appears that this
gene-signature is commonly linked to PTEN, PI(3)K/AKT
and E2F–retinoblastoma protein–p16 pathway, and may
be marginally associated with the subtype of ECs.
Cancer stage is the most import indicator for selecting
an appropriate cancer treatment option for a patient. In
this study, two co-expression networks were significantly
correlated with the stage of ECs. These two network-
regulated signaling events contributed to cell-cycle regu-
lation, antigen processing and TCA cycle, respectively.
From the cell-cycle regulation network, 5 hub genes
were identified including BUB1, FEN1, KIF23, CDC20
and PRC1. BUB1 and CDC20 are involved in the M
phase of mitotic cell cycle and DNA replication, and play
critical roles in the cell-cycle regulation [28]. Altered
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CDC20 may lead to chromosomal instability. BUB1 and
CDC20 are important regulators of the anaphase-promoting
complex (APC) [29]. APC’s function is to trigger the tran-
sition from metaphase to anaphase by tagging critical cell-
cycle proteins for degradation, and maintaining genomic
stability in a normal manner. BUB1 can directly phosphoryl-
ate the APC’s co-activator CDC20, leading to the decreased
activity of APC, which determines the metaphase-to-ana-
phase transition. The overexpression of BUB1 or CDC20 in-
duces misregulation of APC, and is associated with the
chromosomal instability and poor outcomes in breast cancer
patients [30,31]. KIF23 belongs to the kinesin family, and it
is part of the central spindle in a complex that clusters
PRC1 and AURKB together at the spindle midzone to en-
able anaphase in dividing cells and regulation of central
spindle assembly [32]. Abnormal regulation of these genes
may lead to the chromosomal instability, thereby promoting
tumor development and progression.
The pathway of MHC class I presentation is an im-
portant mechanism in determining whether tumors are
able to evade immune response. Down-regulation of
MHC Class I has been described in ovary and cervix
malignancies. Abnormal expression of MHC Class I
genes has been linked to the advanced stage of disease
and poor survival in ovarian cancer [33]. Recently, a
large cohort study of patients with endometrial cancer
indicated that down-regulation of MHC Class I expres-
sion in endometrial cancer patients are correlated to
late-stage ECs [34]. In this study, we identified a group
of hub genes associated with the stage of ECs deriving
from the MHC Class I co-expression network. These
hub genes, PSMB7 and PSMB3, were found to signifi-
cantly regulate the network of antigen processing and to
contribute to Class I MHC mediated processing. Fur-
thermore, we also discovered 3 hub genes (IDH3G,
NDUFV2 and ATP5B) associated with the TCA cycle.
No other study to date has reported that these hub
genes might be associated with cancer, but recent studies
have indicated that the alterations in the TCA cycle en-
zymes may favor tumorigenesis by impacting on cellular
redox state and overall cell metabolism [35,36]. There-
fore, it is reasonable to hypothesize that these hub genes
could be involved with tumor progression.
To identify the signaling pathway through which hub
genes regulated the co-expression network in the pro-
gression of ECs, we compared the gene co-expression
networks between Type I (early-stage, low-grade) and
Type II ECs (late-stage, high-grade) of ECs. In the cell-
cycle regulation network, Type II ECs displayed a distinct
pathway when compared with Type I ECs. However,
BUB1, AURKB, CDC6, CENPA and KIF20A seemed to be
critical regulators for the co-expression network in Type
II compared to Type I ECs. Among these genes, BUB1may play a key role in regulating these genes to promote
tumor formation. The overexpression of BUB1 regulates
AURKB, CENPA, CDC6 and KIF20A in a variety of human
cancers [37-39]. Furthermore, from the antigen processing
and TCA cycle co-expression networks, we found that the
network regulated TCA cycle through the co-regulation of
IDH3G, NDUFV2 and ATP5B, and linked to the pathway
of Cass I MHC antigen processing key players were
PSMB3 and PSMB7 in Type II compared to Type I ECs.
Expression of these genes in Type II ECs may facilitate the
identification of signaling pathways contributing to tumor
progression.
Conclusions
This study used a novel systematic framework to identify
two co-expression networks associated with ECs tumori-
genesis based on large-scale human microarray data. In
addition, a number of novel hub genes in these two
co-expression networks were identified contributing to
three signaling pathways: cell-cycle regulation, antigen
processing and TCA cycle, and presented a high pre-
dictive power in distinguishing grade, type and stage of
ECs. Although Type I and Type II ECs shared similar
genetic information, several critical hub genes were
identified that may contribute to progression of ECs.
Together, these findings provided a clearer and broader
picture of the signaling pathways regulated by co-
expression networks contributing to ECs. Furthermore,
the characterization of these hub genes might infuse
novel insights into the identification of novel clinical
markers and potential therapeutic targets for ECs.
Methods
Data collection and processing
Microarray data sets were systematically searched from
ArrayExpress (http://www.ebi.ac.uk/arrayexpress/) using
the keyword “endometrial cancer”. Only the studies that
presented the raw microarray expression data in humans
(women) were employed in this study. Samples from
both patients with and without cancer were requested
along with phenotypic characteristics of ECs such as
grade, type, and stage. These samples were controlled in
a way that none of the samples had been exposed to any
specific treatment, not subjected to any stimulus, nor
derived from cell lines, thus only from endometrial tissue
of women. A total of 273 microarray datasets from mul-
tiple platforms including Affymetrix, Agilent and Illumina
were merged across platforms as training datasets to un-
cover the predictive cancer signatures (Additional file 1: SI
Materials and Methods). In addition, 65 samples from Illu-
mina and Swegene microarray platforms were utilized as
validation datasets. Therefore, a total of 318 microarray
datasets were effectively used in these studies. All the in-
formation of the datasets are summarized in Table 3 and
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sets measured with multiple platform chips, we selected
genes from all platforms based on the NIH Entrez Gene
ID and used the Cross-Platform Normalization (XPN)
method of Shabalin et al. [40] implemented in the R
package: “CONOR” [41]. These normalization proce-
dures led to a total of 8,920 genes that were selected to
further analysis after data processing. Detailed descrip-
tions of the data preprocessing and normalization are
summarized in Additional file 6: Figure S2 and Additional
file 1: SI Materials and Methods.
Initial data analysis
We reviewed the sample profiles in each of the 273
microarray datasets. From these 273 datasets, at least
four samples corresponding to both classes of one analysis
of interest were selected for additional analyses. Thus,
analyses of interest included cancer versus non-cancer
patients, cancer grade, which was further divided into high
grade (G3, poorly differentiated) versus low grade (G1, wellTable 3 Characteristics of microarray datasets for
platform, sample groups, and grade, type and stage in
endometrial cancers
Characteristics Training dataset
(n = 273)
Validation set A
(n = 40)
Validation set B
(n = 90)
Sample
Control 37 (14%) 20 (50%) 45 (50%)
Case 236 (86%) 20 (50%) 45 (50%)
Gradea
G1 86 (36%) 20 (44%)
G2 43 (18%) - 12 (27%)
G3 52 (22%) - 8 (18%)
Unknown 55 (23%) - 5 (11%)
Typea
T1 113 (48%) 10 (50%) -
T2 84 (36%) 10 (50%) -
Unknown 39 (17%) 0 -
Stagea
IA 31 (13%) 10 (50%) 10 (22%)
IB 37 (16%) - 10 (22%)
IC or late
stage
23 (10%) 10 (50%) 19 (42%)
Unknown 82 (61%) 0 6 (14%)
Platform
Affymetrix 140 - -
Illumina 19 20 -
Agilent 114 - -
Swegene - - 45
aEndometrial cancers are grouped by the grade (degree of differentiation),
type (histopathological types) and stage (status of spread).differentiated), cancer types; Type I (estrogen dependent)
versus Type II (estrogen independent), and cancer stage
(higher than stage 2) versus early stage (lower than stage 2).
After the assignment of samples to classes, we assessed the
differential expression using Student’s t test to identify the
significantly differential expression of gene profiles. False
discovery rates (FDR) were used in these analyses for
correcting for multiple comparisons [42]. All differen-
tially expressed analysis used the “limma” program in
the R-based Bioconductor package to calculate the level
of differential expression [43].
Reconstruction of co-expression network
This study performed WGCNA analysis to construct the
modules of co-expression gene for the EC-associated
networks and their interactions. From the processed
expression files, the networks were formed from the
weighted correlation matrices following the protocols
of WGCNA. Briefly, the WGCNA converts the gene
expression profiles into connection weights that can be
visualized as topology overlap measures (TOM) (Additional
file 7: Figure S3). We chose expression profiles of 4,500
genes in the co-expression network analysis. These
genes were either significantly differentially expressed
between non-cancer and cancer samples (FDR < 0.05
and fold change > 1.5 between two groups) or showed a
large variability in expression. We defined modules
using a hierarchical cluster method, and used the topo-
logical overlap dissimilarity measure (1-TOM) as the
distance measure with a height cutoff value of 0.95 and
a minimum size (gene groups) cutoff value of 100 for
the resulting dendrogram. All network analyses were
implemented in the package WGCNA in the R environ-
ment as previously described [44].
Identification of cancer hub genes
We implemented for the first time an unique systematic
framework that applies the elastic-net regularization-
based approach and WGCNA to take the ECs-specific
gene co-expression networks into account in the process
of identification of cancer hub genes. Our approach con-
tain two major steps. Firstly, we used WGCNA to iden-
tify the cancer hub genes that functionally contribute
to the tumorigenesis of ECs. To distinguish centrally lo-
cated genes (hub genes) of the co-expressed network, we
calculated its scaled connectivity (K) and genes signifi-
cance (GS) using WGCNA. This approach enabled us to
determine the hub genes implicated by both the genetic
marker and network connectivity information.
Secondly, to link these potential hub genes to the
phenotypic characteristics of ECs, the elastic-net analysis
was used to select which of these features were signifi-
cantly associated with phenotypic characteristics of ECs
across the gene co-expression networks. This approach is
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number of variables significantly outweighs the number of
samples. In fact, this approach has been used as a powerful
classification algorithm for large-scale microarray analysis
[45,46]. In addition to all these innovative but highly struc-
tured and systematized approaches and procedures, we
alsoperformed bootstrap analysis, sampling the datasets
with replacements 1,000 times, and calculating the fre-
quency (f) of markers (genes) for inclusion in the model
for each bootstrap sample. Only genes present in more
than the fourth quartile (f > 750) of all bootstrap samples
were selected as ECs-specific hub genes. All elastic-net
analysis used the R package “glmnet” [47]. Full methods
are available in Support information.
Classifier predictive model
Classification performance was assessed with areas under
the receiving operating characteristic (AUC) curve. Using
the penalized logistic regression via the elastic-net, a clas-
sification model was built, and its discriminatory capacity
was first estimated with a strict 10-fold cross-validation
methodology (as described in Additional file 1: Materials
and Methods). The resulting model was next tested on in-
dependent datasets using the cancer hub genes as a model
input to predict the classes of particular samples relevant
to the process of neoplastic transformation and progres-
sion in ECs.
Pathway analysis
The network was visualized through Cytoscape Soft-
ware 3.0.1 [48]. This study used the Cluepedia plug-in
in Cytoscape to identify potential association to path-
ways of cancer hub genes [49]. CluePedia organizes a
functionally grouped pathway with cancer hub genes
by integrating heterogeneous expression data and func-
tional network information.Additional files
Additional file 1: SI Materials and Methods.
Additional file 2: Table S1. Genes differentially expressed between
tissues of cancer and non-cancer samples subjects.
Additional file 3: Table S2. List of potential hub genes in the WGCNA
network, their gene significance and connectivity to each module.
Additional file 4: Figure S1. 10-fold cross validation to predict the (A)
grade, (B) type, (C, D) stage of ECs using grade-, type- and stage-related
cancer hub genes. The ROC curve of stage II is predicted from the cancer
hub genes derived from Mblue.
Additional file 5: Table S3. List of microarray experiments used for
meta-analysis.
Additional file 6: Figure S2. Detailed process of matching probes
among different microarray platforms.
Additional file 7: Figure S3. Topological overlap matrix (TOM) plot of
the network connections. Genes in the rows and columns are sorted by
the clustering tree.Competing interests
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